BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select®, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer (NSCLC) in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56378) on January 06, 2026, and is solely responsible for the information contained therein.